News Quantified

SYRS – syros pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal [Yahoo! Finance]

Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.

The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions

Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations

-2.3%

BEAT

-1.8%

BEAT

10.6%

BEAT

-8.5%

MISS

Form 4 Syros Pharmaceuticals, For: Nov 19 Filed by: Quirk Gerald E

Form 4 Syros Pharmaceuticals, For: Nov 18 Filed by: Stephens Kristin

Form 4 Syros Pharmaceuticals, For: Nov 18 Filed by: Chee Conley

Form 4 Syros Pharmaceuticals, For: Nov 18 Filed by: Roth David

Form 4 Syros Pharmaceuticals, For: Nov 18 Filed by: Haas Jason

Top News Gainers

12/18 Form 8-K Syros Pharmaceuticals, For: Dec 17 16.2%

12/18 Syros Pharmaceuticals Inc (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at Cowen Inc. 15.7%

8/1 Q2/2019 6/30/2019 EPS -0.470 ZacksConsensus -0.410 ActVsEst (0.060) - Miss 13.4%

12/20 Syros Announces Appointment of Mark Alles to Its Board of Directors 11.6%

8/6 Syros to Present at 2019 Wedbush PacGrow Healthcare Conference 10.6%

3/6 Syros Pharmaceuticals Inc (NASDAQ: SYRS) had its "hold" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock. 9.8%

4/2 Form SC 13G Syros Pharmaceuticals, Filed by: Point72 Asset Management, L.P. 8.9%

6/12 Syros to Present at JMP Securities Life Sciences Conference 7.1%

1/12 Syros Announces Strategic Priorities and Expected Milestones 6.9%

1/14 Syros Pharmaceuticals Inc (NASDAQ: SYRS) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 6.3%

Top News Decliners

10/17 Syros Announces Update on Selective CDK7 Inhibitor Portfolio -34.3%

10/24 Form 8-K Syros Pharmaceuticals, For: Oct 24 -15.2%

7/14 Syros Pharmaceuticals Inc (NASDAQ: SYRS) is now covered by analysts at Roth Capital. They set a "buy" rating and a $17.00 price target on the stock. -14.1%

3/6 Form 424B5 Syros Pharmaceuticals, -12.2%

2/24 Syros to Present at Upcoming Investor Conferences in March -9.0%

6/11 Syros Pharmaceuticals Inc (NASDAQ: SYRS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.4%

5/7 New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers -6.4%

10/18 Syros Pharmaceuticals Inc (NASDAQ: SYRS) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -6.3%

12/2 Form 8-K Syros Pharmaceuticals, For: Dec 02 -5.7%

10/8 Syros Pharmaceuticals Inc (NASDAQ: SYRS) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -5.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day